Non-inferior clinical outcomes of immune checkpoint inhibitors in non-small cell lung cancer patients with interstitial lung disease-Reference-Cited by-同舟云学术

Non-inferior clinical outcomes of immune checkpoint inhibitors in non-small cell lung cancer patients with interstitial lung disease

Published:2021-05 Issue: Volume:155 Page:120-126
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Tasaka Yuri^ORCID,Honda Takayuki^ORCID,Nishiyama Naoki,Tsutsui Toshiharu,Saito Hiroaki,Watabe Haruna,Shimaya Kazuhiro,Mochizuki Akifumi,Tsuyuki Shun,Kawahara Tatsuo,Sakakibara Rie,Mitsumura Takahiro^ORCID,Okamoto Tsukasa^ORCID,Kobayashi Masayoshi,Chiaki Tomoshige^ORCID,Yamashita Takaaki,Tsukada Yoshikazu,Taki Reiko,Jin Yasuto,Sakashita Hiroyuki,Natsume Ichirou,Saitou Kazuhito,Miyashita Yoshihiro,Miyazaki Yasunari^ORCID

Funder

MSD K.K.

Taiho Pharmaceutical

Ono Pharmaceutical

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference32 articles.

1. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods;Ferlay;Int. J. Cancer,2019

2. Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis;Antonia;Lancet Oncol.,2019

3. Five-year overall survival for patients with advanced non‒small-cell lung Cancer Treated with pembrolizumab: results from the phase I KEYNOTE-001 study;Garon;J. Clin. Oncol.,2019